Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
about
Immunopathogenesis of granulomas in chronic autoinflammatory diseases.Immune response patterns in non-communicable inflammatory skin diseases.Candidate Serum Markers in Early Crohn's Disease: Predictors of Disease Course.Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
P2860
Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@en
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@nl
type
label
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@en
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@nl
prefLabel
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@en
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@nl
P2093
P2860
P356
P1476
Infliximab therapy balances re ...... soluble TNFR2 in sarcoidosis.
@en
P2093
A D M Vorselaars
A M E Claessen
A Verwoerd
C H M van Moorsel
H A Crommelin
J C Grutters
P2860
P304
P356
10.1111/CEI.12808
P577
2016-05-09T00:00:00Z